In the meeting, as part of stakeholder consultations, the committee desired to have the views of the Organisation of Pharmaceutical Producers of India (OPPI), Indian Pharmaceutical Alliance (IPA), and Indian Drug Manufacturers Association (IDMA) — the three lobbies representing domestic as well as foreign drugmakers in India
